Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Drug Resistance, Neoplasm
  • Lung Neoplasms
  • Quinazolines
  • Receptor, Epidermal Growth Factor

abstract

  • In EGFR mutated tumors resistant to gefitinib 250 mg/d, a switch to erlotinib 150 mg/d does not lead to responses in most patients. These findings are consistent with preclinical models, because the common mechanisms of TKI resistance (T790M and MET amplification) in vitro are not inhibited by clinically achievable doses of gefitinib or erlotinib. Alternative strategies to overcome TKI resistance must be evaluated.

publication date

  • November 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2596582

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-08-1455

PubMed ID

  • 18981003

Additional Document Info

start page

  • 7060

end page

  • 7

volume

  • 14

number

  • 21